Entera Bio (STU:5DT) Pre-Tax Income : €-8.81 Mil (TTM As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Entera Bio Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Entera Bio's pretax income for the three months ended in Dec. 2024 was €-2.24 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was €-8.81 Mil. Entera Bio's pretax margin was -2,870.51%.

During the past 10 years, Entera Bio's highest Pretax Margin was -2060.80%. The lowest was -9652.24%. And the median was -3820.78%.

Entera Bio Pre-Tax Income Historical Data

The historical data trend for Entera Bio's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entera Bio Pre-Tax Income Chart

Entera Bio Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Pre-Tax Income

Get a 7-Day Free Trial

-9.20

-10.84

-12.21

-8.13

-9.10

Entera Bio Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Pre-Tax Income	Get a 7-Day Free Trial															-1.83	-1.86	-1.99	-2.72	-2.24

Competitive Comparison of Entera Bio's Pre-Tax Income

For the Biotechnology subindustry, Entera Bio's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entera Bio's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entera Bio's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Entera Bio's Pre-Tax Income falls into.

Save Embed

;

Save Embed

;

Entera Bio Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Entera Bio's Pretax Income for the fiscal year that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-9.154	+	0	+	0	+	0	+	0.055999999999999
	=	-9.10

Entera Bio's Pretax Income for the quarter that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-2.232	+	0	+	-0.007	+	0	+	4.4408920985006E-16
	=	-2.24

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-8.81 Mil.

Entera Bio (STU:5DT) Pre-Tax Income Explanation

Entera Bio's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-2.239	/	0.078
	=	-2,870.51%

During the past 10 years, Entera Bio's highest Pretax Margin was -2060.80%. The lowest was -9652.24%. And the median was -3820.78%.

Entera Bio Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Entera Bio's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Entera Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entera Bio Ltd (STU:5DT) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

ENTX:USA 5DT:Germany

Address

Minrav Building - Fifth Floor, Kiryat Hadassah, Jerusalem, ISR, 9112002

Website

https://www.enterabio.com

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Entera Bio Headlines

No Headlines